Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

H1 2024-25 results in line with expectations Operating verticals revenues of €600m up 3.9% like-for-like1 Adjusted EBITDA margin of 55.2% FY 2024-25 objectives confirmed ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

NeuroOne Medical Technologies Corporation ( NASDAQ: NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET ...

Good morning, and welcome to the Conference Call for Tate & Lyle's Q3 Trading Statement. Your speakers today are Nick Hampton, Chief Executive; and Sarah Kuijlaars, Chief Financial Officer. I will now ...

The February 2025 Model Shadow Stock Portfolio Update is now available online.

Iga Swiatek will look to extend her victorious run in Doha at Qatar Open 2025, where she will aspire to become the first four ...

Get Latest and Breaking News about Cricket and Football. Todays Top News Headlines about Sports, News on Indian Sports, Photos and Videos of Sports. News about Virat Kohli, MS Dhoni, Rohit Sharma, ...

We expect the USD to continue to be supported in the coming week and base this assumption mainly on the market expectations ...

The Company's Board of Directors (the "Board”) approved payment of the $0.0075 per share per month dividend beginning in ...